Stereotactic Body Radiation Therapy in Oligometastatic Ovarian Cancer: A Promising Therapeutic Approach

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

OBJECTIVE: Stereotactic body radiation therapy (SBRT) has been successfully used to treat oligometastases of several primary tumors, but few experiences have been described in patients with gynecological oligometastatic cancer, particularly in ovarian neoplasm. The aim of this study was to evaluate the role of this new radiotherapy modality in a series of oligometastatic ovarian cancer patients.

MATERIALS AND METHODS: Clinical records of patients affected by oligometastatic ovarian carcinoma treated with SBRT were reviewed.

RESULTS: Twenty-six patients with 44 metastatic lesions (lymph nodes, 63.6%; liver, 31.8%; and lung, 4.5%) treated with SBRT between January 2011 and May 2017 were analyzed. After a median follow-up period of 28.5 months (range, 6-86 months), 17 patients (65.4%) were still alive at time of analysis: 6 are without evidence of disease, 11 experienced a disease progression. Eight patients died of disease, 1 died because of an heart attack while being disease free. The median local control (LC) was not reached. One-, 2-, and 5-year LCs were 92.9%. Median progression-free survival was 19 months, with 1-year progression-free survival of 69.3% and 38% at 2 years, 19% at 5 years. Median overall survival was 64.5 months, with all patients alive after 1 year, 92.7% at 2 years, and 61.7% at 5 years. Five (11.3%) cases experienced G2 toxicity; most common adverse effect was nausea and vomiting (3 cases [6.8%]) followed by abdominal pain (2 cases [4.5%]). None of the patients had grade 3 or grade 4 acute or late toxicity.

CONCLUSIONS: In conclusion, SBRT is a feasible and safe approach for selected cases of oligometastatic ovarian cancer, with satisfactory results in terms of LC and disease free survival.

Original languageEnglish
Pages (from-to)1507-1513
Number of pages7
JournalInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Volume28
Issue number8
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

Ovarian Neoplasms
Radiotherapy
Disease-Free Survival
Therapeutics
Nausea
Abdominal Pain
Vomiting
Disease Progression
Neoplasms
Lymph Nodes
Myocardial Infarction
Carcinoma
Lung
Survival
Liver

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Cite this

@article{47980d1046db46088d261a12985fcf9b,
title = "Stereotactic Body Radiation Therapy in Oligometastatic Ovarian Cancer: A Promising Therapeutic Approach",
abstract = "OBJECTIVE: Stereotactic body radiation therapy (SBRT) has been successfully used to treat oligometastases of several primary tumors, but few experiences have been described in patients with gynecological oligometastatic cancer, particularly in ovarian neoplasm. The aim of this study was to evaluate the role of this new radiotherapy modality in a series of oligometastatic ovarian cancer patients.MATERIALS AND METHODS: Clinical records of patients affected by oligometastatic ovarian carcinoma treated with SBRT were reviewed.RESULTS: Twenty-six patients with 44 metastatic lesions (lymph nodes, 63.6{\%}; liver, 31.8{\%}; and lung, 4.5{\%}) treated with SBRT between January 2011 and May 2017 were analyzed. After a median follow-up period of 28.5 months (range, 6-86 months), 17 patients (65.4{\%}) were still alive at time of analysis: 6 are without evidence of disease, 11 experienced a disease progression. Eight patients died of disease, 1 died because of an heart attack while being disease free. The median local control (LC) was not reached. One-, 2-, and 5-year LCs were 92.9{\%}. Median progression-free survival was 19 months, with 1-year progression-free survival of 69.3{\%} and 38{\%} at 2 years, 19{\%} at 5 years. Median overall survival was 64.5 months, with all patients alive after 1 year, 92.7{\%} at 2 years, and 61.7{\%} at 5 years. Five (11.3{\%}) cases experienced G2 toxicity; most common adverse effect was nausea and vomiting (3 cases [6.8{\%}]) followed by abdominal pain (2 cases [4.5{\%}]). None of the patients had grade 3 or grade 4 acute or late toxicity.CONCLUSIONS: In conclusion, SBRT is a feasible and safe approach for selected cases of oligometastatic ovarian cancer, with satisfactory results in terms of LC and disease free survival.",
author = "Cristina Iftode and DʼAgostino, {Giuseppe R.} and Angelo Tozzi and Tiziana Comito and Ciro Franzese and {De Rose}, Fiorenza and Davide Franceschini and {Di Brina}, Lucia and Stefano Tomatis and Marta Scorsetti",
year = "2018",
month = "10",
day = "1",
doi = "10.1097/IGC.0000000000001324",
language = "English",
volume = "28",
pages = "1507--1513",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Stereotactic Body Radiation Therapy in Oligometastatic Ovarian Cancer

T2 - A Promising Therapeutic Approach

AU - Iftode, Cristina

AU - DʼAgostino, Giuseppe R.

AU - Tozzi, Angelo

AU - Comito, Tiziana

AU - Franzese, Ciro

AU - De Rose, Fiorenza

AU - Franceschini, Davide

AU - Di Brina, Lucia

AU - Tomatis, Stefano

AU - Scorsetti, Marta

PY - 2018/10/1

Y1 - 2018/10/1

N2 - OBJECTIVE: Stereotactic body radiation therapy (SBRT) has been successfully used to treat oligometastases of several primary tumors, but few experiences have been described in patients with gynecological oligometastatic cancer, particularly in ovarian neoplasm. The aim of this study was to evaluate the role of this new radiotherapy modality in a series of oligometastatic ovarian cancer patients.MATERIALS AND METHODS: Clinical records of patients affected by oligometastatic ovarian carcinoma treated with SBRT were reviewed.RESULTS: Twenty-six patients with 44 metastatic lesions (lymph nodes, 63.6%; liver, 31.8%; and lung, 4.5%) treated with SBRT between January 2011 and May 2017 were analyzed. After a median follow-up period of 28.5 months (range, 6-86 months), 17 patients (65.4%) were still alive at time of analysis: 6 are without evidence of disease, 11 experienced a disease progression. Eight patients died of disease, 1 died because of an heart attack while being disease free. The median local control (LC) was not reached. One-, 2-, and 5-year LCs were 92.9%. Median progression-free survival was 19 months, with 1-year progression-free survival of 69.3% and 38% at 2 years, 19% at 5 years. Median overall survival was 64.5 months, with all patients alive after 1 year, 92.7% at 2 years, and 61.7% at 5 years. Five (11.3%) cases experienced G2 toxicity; most common adverse effect was nausea and vomiting (3 cases [6.8%]) followed by abdominal pain (2 cases [4.5%]). None of the patients had grade 3 or grade 4 acute or late toxicity.CONCLUSIONS: In conclusion, SBRT is a feasible and safe approach for selected cases of oligometastatic ovarian cancer, with satisfactory results in terms of LC and disease free survival.

AB - OBJECTIVE: Stereotactic body radiation therapy (SBRT) has been successfully used to treat oligometastases of several primary tumors, but few experiences have been described in patients with gynecological oligometastatic cancer, particularly in ovarian neoplasm. The aim of this study was to evaluate the role of this new radiotherapy modality in a series of oligometastatic ovarian cancer patients.MATERIALS AND METHODS: Clinical records of patients affected by oligometastatic ovarian carcinoma treated with SBRT were reviewed.RESULTS: Twenty-six patients with 44 metastatic lesions (lymph nodes, 63.6%; liver, 31.8%; and lung, 4.5%) treated with SBRT between January 2011 and May 2017 were analyzed. After a median follow-up period of 28.5 months (range, 6-86 months), 17 patients (65.4%) were still alive at time of analysis: 6 are without evidence of disease, 11 experienced a disease progression. Eight patients died of disease, 1 died because of an heart attack while being disease free. The median local control (LC) was not reached. One-, 2-, and 5-year LCs were 92.9%. Median progression-free survival was 19 months, with 1-year progression-free survival of 69.3% and 38% at 2 years, 19% at 5 years. Median overall survival was 64.5 months, with all patients alive after 1 year, 92.7% at 2 years, and 61.7% at 5 years. Five (11.3%) cases experienced G2 toxicity; most common adverse effect was nausea and vomiting (3 cases [6.8%]) followed by abdominal pain (2 cases [4.5%]). None of the patients had grade 3 or grade 4 acute or late toxicity.CONCLUSIONS: In conclusion, SBRT is a feasible and safe approach for selected cases of oligometastatic ovarian cancer, with satisfactory results in terms of LC and disease free survival.

UR - http://www.scopus.com/inward/record.url?scp=85055659219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055659219&partnerID=8YFLogxK

U2 - 10.1097/IGC.0000000000001324

DO - 10.1097/IGC.0000000000001324

M3 - Article

C2 - 30036231

AN - SCOPUS:85055659219

VL - 28

SP - 1507

EP - 1513

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 8

ER -